BIOMARKER FOR PREDICTING EFFECTS OF ANTI-PD-1 ANTIBODY/ANTI-PD-L1 ANTIBODY THERAPY
Number of patents in Portfolio can not be more than 2000
United States of America Patent
Stats
-
N/A
Issued Date -
Jan 7, 2021
app pub date -
Feb 7, 2019
filing date -
Feb 14, 2018
priority date (Note) -
Published
status (Latency Note)
Importance
Abstract
An object of the present invention is to provide a novel marker that can be used to predict the effect of anti-PD-1 antibody/anti-PD-L1 antibody therapy with high sensitivity, and use thereof. Provided is a biomarker for predicting the effect of anti-PD-1 antibody/anti-PD-L1 antibody therapy, including an immunoglobulin superfamily containing leucine-rich repeat (ISLR).
First Claim
Family
International Classification(s)
Cited Art Landscape
Patent Citation Ranking
Recipient Email Address
Recipient Email Address
Comment
Recipient Email Address
Add to Portfolio(s)
To add this patent to one, or more, of your portfolios, simply click the add button.
This Patent is in these Portfolios:
Add to additional portfolios:
Last Refreshed On:
Changes done successfully